Navigation Links
FDA approves VYVANSE, first and only once-daily prodrug stimulant to treat ADHD in adults
Date:4/23/2008

Basingstoke, U.K. and Philadelphia, PA April 23, 2008 Shire plc (LSE: SHP, NASDAQ: SHPGY,), the global specialty biopharmaceutical company, today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for VYVANSE (lisdexamfetamine dimesylate), for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults. VYVANSE, introduced in July 2007 for the treatment of ADHD in children aged 6 to 12 years, is now the first and only once-daily prodrug stimulant approved to treat adults with ADHD. In its first eight months of availability, more than one million VYVANSE prescriptions have been filled.

We are very pleased with this FDA approval of the adult indication for VYVANSE, said Matthew Emmens, Chief Executive Officer of Shire. This approval provides physicians a new treatment option that can help their adult patients by significantly improving their ADHD symptoms. VYVANSE has been well accepted by the medical community. With Shires experience as a leader in the development and commercialization of ADHD medications, we are confident that this approval for adult patients will help continue to increase prescription share and volume of VYVANSE.

Many people may think of ADHD as only a childhood disorder but the fact is that the majority of children diagnosed with ADHD still have symptoms as an adult. These symptoms can significantly impact them at work, home and in relationships, where they have important responsibilities, said David W. Goodman, assistant professor of psychiatry and behavioral sciences at Johns Hopkins University School of Medicine and director of the Adult Attention Deficit Disorder Center of Maryland. The good news is that in a clinical study with adults, one daily dose of VYVANSE significantly improved ADHD symptoms of inattention, such as the ability to focus and organize, as well as hyperactivity and impulsivity.

Since VYVANSE became available for children with ADHD in
'/>"/>

Contact: Matthew Cabrey, Shire
484-595-8248
Porter Novelli
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. FDA Approves First Anti-Psychotic for Kids
2. FDA Approves New Roche West Nile Virus Blood Screening Test
3. FDA Approves Osteoporosis Drug to Cut Breast Cancer Risk
4. FDA Approves LEVAQUIN(R) Short-Course Therapy for Treatment of Complicated Urinary Tract Infections and Acute Pyelonephritis
5. FDA Approves SOMA(R) (carisoprodol) 250 mg
6. FDA Approves Expanded Label for FluMist(R) to Include Children Two to Five Years of Age
7. FDA approves expanded label for FluMist (influenza virus vaccine live, intranasal) to include childr
8. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
9. ABIH Approves Certification Credit for SSPC Training Courses
10. FDA Approves REALIZE(TM) Adjustable Gastric Band for Morbid Obesity
11. FDA Approves New Flu Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... August 27, 2015 , ... ... scheduled for October 27-29, 2015 in San Jose, CA. The first event ... focus on the void that exists where battery development and energy storage innovation ...
(Date:8/27/2015)... ... August 27, 2015 , ... In addition to its existing Doctor ... a third doctoral program at its main campus in Reading: Doctor of Nursing Practice. ... designed to prepare advanced practice nurses for the highest level of clinical nursing practice. ...
(Date:8/27/2015)... ... ... Pinellas, located at 1395 South Pinellas Avenue in Tarpon Springs, will open a free-standing emergency ... at US Highway 19 North and Highlands Boulevard, less than eight miles from the main ... is slated to begin in September 2015. , The new 24-bed facility will ...
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... NetDimensions ... , “The companies selected have the platforms required not only to effectively deliver, curate ... Taylor, President of Training Industry, Inc. , For six consecutive years, NetDimensions has ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... they have launched their new corporate website http://www.Z-Medica.com , to further support ... website that was launched last year. , “We launched a branded website ...
Breaking Medicine News(10 mins):Health News:Infocast Hosting First Conference Dedicated to Powering Wearable Devices & the IoT 2Health News:Alvernia University Now Offering Three Doctoral Degree Programs 2Health News:Florida Hospital North Pinellas is Opening a New Free-Standing Emergency Room in Palm Harbor 2Health News:Florida Hospital North Pinellas is Opening a New Free-Standing Emergency Room in Palm Harbor 3Health News:NetDimensions Named Among Top 20 Learning Portal Companies of 2015 2Health News:NetDimensions Named Among Top 20 Learning Portal Companies of 2015 3Health News:Z-Medica® Launches New Corporate Website 2
... Heavy alcohol consumption, specifically three or more glasses of ... of death from pancreatic cancer, according to a report ... Internal Medicine, one of the JAMA/Archives journals. ... is causally related to several cancers, including oral cavity, ...
... , , , , ... AUDIO: Washington University,s Victoria Fraser, MD, talks about ... , , , , ... , , , , , , ...
... March 14 (HealthDay News) -- A lack of vitamin ... but levels of the vitamin don,t decrease as the ... insufficiency has been associated with a variety of clinical ... strength, mood and cognitive dysfunction, autoimmune disorders such as ...
... HealthDay Reporter , MONDAY, March 14 (HealthDay News) -- Women ... fatty acids found in that meal choice -- have a ... suggests. This latest evidence of a protective link between ... found the same benefit. In this study, Harvard researchers performed ...
... March 14, 2011 -- Some physicians are prescribing opioids such ... a new study led by St. Michael,s Hospital and the ... opioid-related deaths occur among patients treated by physicians who frequently ... may not be doing so safely. "We found that ...
... technique called microdissection testicular sperm extraction (TESE) can effectively ... of adult male childhood cancer survivors who were previously ... result, many of the men were subsequently able to ... The findings offer a new option for many cancer ...
Cached Medicine News:Health News:Heavy drinking associated with increased risk of death from pancreatic cancer 2Health News:Novel strategies target health care-associated infections 2Health News:Novel strategies target health care-associated infections 3Health News:Novel strategies target health care-associated infections 4Health News:Study: Lack of Vitamin D May Precede Onset of Parkinson's 2Health News:Eating Fish Might Protect Your Eyesight 2Health News:Eating Fish Might Protect Your Eyesight 3Health News:Painkiller prescribing varies dramatically among family physicians: study 2Health News:Surgical technique helps adult male survivors of childhood cancer regain fertility 2Health News:Surgical technique helps adult male survivors of childhood cancer regain fertility 3
(Date:8/27/2015)... NEWARK, N.J. , Aug. 27, 2015  Symbiomix ... Phase 3 clinical study, the second pivotal trial of ... the treatment of bacterial vaginosis (BV). Earlier this year ... for SYM-1219. Symbiomix expects to finish this second pivotal ... a New Drug Application (NDA) filing with the U.S. ...
(Date:8/27/2015)... -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN ) today announced that ... a corporate overview and business update at two investor conferences ... . , 22 nd Annual NewsMakers in ... Millennium Broadway Hotel. , Rodman & Renshaw Annual Global ... Regis Hotel. To access the live audio webcast ...
(Date:8/26/2015)... PUNE, India , August 27, 2015 ... market research reports reviewing the genotyping technology, ... as well as single nucleotide polymorphism (SNP) ... ReportsnReports.com. Complete report on genotyping ... spread across 200 pages, profiling 10 major ...
Breaking Medicine Technology:Symbiomix Therapeutics Completes Enrollment in Second Pivotal Trial of SYM-1219 for Bacterial Vaginosis, and Receives FDA Fast Track Designation 2Symbiomix Therapeutics Completes Enrollment in Second Pivotal Trial of SYM-1219 for Bacterial Vaginosis, and Receives FDA Fast Track Designation 3Symbiomix Therapeutics Completes Enrollment in Second Pivotal Trial of SYM-1219 for Bacterial Vaginosis, and Receives FDA Fast Track Designation 4SciClone To Present At Two Investor Conferences On September 10, 2015 2Genotyping Market Forecast to Grow at 22.3% CAGR to 2020 2Genotyping Market Forecast to Grow at 22.3% CAGR to 2020 3Genotyping Market Forecast to Grow at 22.3% CAGR to 2020 4Genotyping Market Forecast to Grow at 22.3% CAGR to 2020 5
... The law firm of Childers, Schlueter & Smith, LLC of ... will be held during the week of July 26, 2010 .  The ... States District Court, Northern District of Georgia , Atlanta Division. , ... The lawsuit alleges that the drug makers and ...
... Inc. (NYSE Amex: MHH ) ("Mastech"), a national provider of Information Technology ... discuss the results of its second quarter ended June 30, 2010 . ... 9:00 a.m. Eastern Time and will be hosted by Mr. ... , , ...
Cached Medicine Technology:Childers, Schlueter & Smith, LLC Set for Reglan/metoclopramide Jury Trial Involving Woman's Development of Tardive Dyskinesia 2Mastech Holdings, Inc. to Discuss Second Quarter 2010 Financial Results on July 28, 2010 2
... (IGF-I or somatomedin C) is a 7.6 kDa ... as a potent mitogen of cellular proliferation, exerting ... In the circulation, IGF-I is bound to IGF-binding ... of IGF-I by modulating the interaction of IGF-I ...
Inquire...
... table comes in two modelsthe BT4, which ... BT5, which offers five. With the simple ... to suit your needs. Both models ... side rails, ankle/foot supports, adjustable arm boards, ...
... A revolutionary urological imaging system ... that translate into improved patient ... 1k imaging technology physicians and ... see more anatomical detail and ...
Medicine Products: